HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Phototherapy for ABO haemolytic hyperbilirubinaemia.

Abstract
The efficacy of 'standard' daylight phototherapy and 'high intensity' blue light phototherapy for neonatal jaundice from ABO-HD, or of a non-haemolytic nature was evaluated. Altogether 77 full-term infants with ABO-HD and 3,020 with non-haemolytic jaundice were studied. Both groups of infants responded well to standard daylight phototherapy; the response in non-haemolytic hyperbilirubinaemia was significantly greater. High intensity blue light phototherapy was significantly more effective in reducing bilirubin levels than standard daylight phototherapy in both group of infants with no failure being encountered. Four infants with non-haemolytic jaundice did not respond adequately to white light (1.4/1,000); they needed high intensity blue light for adequate response. Bilirubin rebound was mild. Four infants in the blue light group needed a second exposure (28.3/1,000) compared with 20 in the white light group (6.9/1,000), a difference that was significant. Standard white light phototherapy is usually adequate for ABO-HD as well as non-haemolytic hyperbilirubinaemia. High intensity blue light would be preferable where a more rapid and greater response is desirable.
AuthorsK L Tan, G C Lim, K W Boey
JournalBiology of the neonate (Biol Neonate) Vol. 61 Issue 6 Pg. 358-65 ( 1992) ISSN: 0006-3126 [Print] Switzerland
PMID1525269 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • ABO Blood-Group System
  • Bilirubin
Topics
  • ABO Blood-Group System
  • Bilirubin (blood)
  • Erythroblastosis, Fetal (blood, complications, therapy)
  • Female
  • Humans
  • Infant, Newborn
  • Jaundice, Neonatal (blood, etiology, therapy)
  • Male
  • Phototherapy (methods)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: